M54.10 Insurance Policy Changes

ICD-10 M54.10 is officially defined as "Radiculopathy, site unspecified." code M54.10 is referenced in 8 tracked payer policy changes from Excellus BlueCross BlueShield and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M54.10 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 15, 2026Medium impact
Radiofrequency Facet and Sacroiliac Joint Ablation/ Denervation - (Effective Date - 2026-10-15) 7.01.42
Facet joint radiofrequency denervation is medically appropriate for facet-mediated cervical, thoracic or lumbar axial pain that has persisted at least three months despite at least four weeks of conservative treatment in the past three months, after two sequential diagnostic facet joint injections or medial branch blocks at the same level each gave at least 80% relief. Repeat denervation requires at least 50% pain relief lasting at least 12 weeks after the prior procedure and at least six months after it, and it is considered not medically necessary when more than two denervations occur at the same level in a rolling 12-month period. Pulsed, endoscopic, cryoablation, chemical, laser and cooled radiofrequency techniques are considered investigational, as are radiofrequency ablation of the sacroiliac joint nerves and intraosseous basivertebral nerve ablation for vertebrogenic back pain.
Aetna · Identified Oct 26, 2026Medium impact
Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0735 considers pulsed radiofrequency experimental, investigational, or unproven for all indications in its list, because its effectiveness has not been established. The list includes indications such as carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and headache. The policy also considers the Stimpod NMS460 nerve stimulator for post-amputation pain, combined ganglion impar block and pulsed radiofrequency for pudendal neuralgia, and combined platelet-rich plasma to the Gasserian ganglion and pulsed radiofrequency for trigeminal neuralgia experimental, investigational, or unproven.
Aetna · Identified Oct 16, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)
Aetna considers TENS units medically necessary durable medical equipment when used as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic, intractable pain not adequately responsive to other methods. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when all listed criteria are met. Percutaneous electrical nerve stimulation is considered medically necessary for chronic low back pain secondary to degenerative disc disease for up to a 30-day period within a multi-modality rehabilitation program, and for diabetic neuropathy or neuropathic pain that has not responded to listed medications. Many other electrical stimulation devices and indications are listed as experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Nerve Blocks (CPB 0863, reviewed 2026-07-23)
Aetna Clinical Policy Bulletin 0863 covers nerve blocks and lists which ones it considers medically necessary. Covered uses include adductor canal, femoral, fascia iliaca, erector spinae plane and transversus abdominis plane blocks for post-operative pain after specific surgeries, and celiac plexus block for cancer pain, while peripheral nerve blocks for chronic pain are covered only as an active component of a comprehensive pain management program. Blocks listed as experimental and investigational include genicular nerve blocks and peripheral nerve blocks used as the sole treatment for chronic non-malignant pain, because the effectiveness of these approaches has not been established.
Aetna · Identified Aug 16, 2026Medium impact
Transforaminal Epidural Injections (CPB 0722, reviewed 2025-10-20)
Aetna considers diagnostic selective transforaminal epidural steroid injections (TFESIs) with imaging guidance medically necessary for chronic radiculopathy when the diagnosis remains uncertain after standard evaluation, and considers an initial therapeutic TFESI medically necessary when physical therapy and non-narcotic analgesics have failed or become intolerant and the radicular pain is consistent with radiologic findings. Additional therapeutic TFESIs are medically necessary when the initial injection produced at least two of the following for at least 2 weeks: 50% or greater pain relief, increased level of function or physical activity, or reduced pain medication use and/or additional medical care such as physical therapy or chiropractic care. A maximum of twelve TFESIs per spinal region is considered medically necessary, administered during a maximum of three sessions for an episode of pain lasting six months, and TFESI sessions more frequent than every two weeks are considered not medically necessary.
Aetna · Identified Aug 15, 2026Medium impact
Pulsed Radiofrequency (CPB 0735, reviewed 2025-10-29)
Aetna considers pulsed radiofrequency (PRF) experimental, investigational, or unproven for all indications listed in CPB 0735, including carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and chronic migraine. The policy also lists the Stimpod NMS460 nerve stimulator and a wearable pulsed radiofrequency therapy device for post-amputation pain as experimental, investigational, or unproven, and it gives the same status to combined ganglion impar block and PRF for pudendal neuralgia and to combined platelet-rich plasma to the Gasserian ganglion and PRF for trigeminal neuralgia. There are no specific CPT or HCPCS codes for pulsed radiofrequency, and the policy lists ICD-10 codes that are not covered for the indications listed in the CPB.
Aetna · Identified Aug 14, 2026Medium impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)
Aetna clinical policy bulletin 0805 considers pudendal nerve decompression experimental, investigational, or unproven for indications including chronic pelvic pain, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder, pudendal neuralgia, and vulvodynia. The policy also considers pudendal nerve hydrodissection for chronic pelvic pain syndrome and urinary incontinence, and pudendal neurolysis for persistent genital arousal disorder and pudendal nerve entrapment syndrome, experimental, investigational, or unproven. The policy does not apply to pudendal nerve blocks used in obstetrics and other operative procedures.
Aetna · Identified Nov 2, 2026Low impact
Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)
Aetna's clinical policy bulletin 0805 on pudendal nerve decompression was reviewed on 10/28/2026. It treats pudendal nerve decompression, hydrodissection and neurolysis as experimental, investigational or unproven for chronic pelvic pain, pudendal neuralgia, interstitial cystitis, penile numbness and erectile dysfunction, persistent genital arousal disorder and vulvodynia, and it lists three related CPT codes as not covered for those indications. The source does not state an effective date for a change or describe a coverage change in this review.

Watch M54.10

Get one email when a payer policy names M54.10, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code M54.10?

There are 8 tracked policy changes affecting code M54.10, including updates from Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M54.10?

Payers that have issued tracked updates for code M54.10 include: Excellus BlueCross BlueShield, Aetna.

How do I get notified when code M54.10 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M54.10. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M54.10?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Radiofrequency Facet and Sacroiliac Joint Ablation/ Denervation - (Effective Date - 2026-10-15) 7.01.42

Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)

Nerve Blocks (CPB 0863, reviewed 2026-07-23)

Transforaminal Epidural Injections (CPB 0722, reviewed 2025-10-20)

Pulsed Radiofrequency (CPB 0735, reviewed 2025-10-29)

Pudendal Nerve Decompression (CPB 0805, reviewed 2025-11-20)

Pudendal Nerve Decompression (CPB 0805, reviewed 2026-10-28)

What insurance policy changes affect code M54.10?

Which payers have updated policy for code M54.10?

How do I get notified when code M54.10 policy changes?

Why do payers change policies for code M54.10?